Tempus ECG-AF vs QFR
AI Verdict
Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if you need to proactively identify elderly patients at increased risk of developing new-onset atrial fibrillation within the next year. This tool is ideal for screening patients aged 65 or older without a prior AF diagnosis, using standard 12-lead ECGs to support earlier intervention and management strategies.
View Tempus ECG-AF →Choose QFR if…
Choose QFR if you require advanced functional assessment of coronary artery lesions based on X-ray angiographic images. This software is best suited for cardiologists in the cath lab setting who need to quantify the hemodynamic significance of stenoses to guide revascularization decisions.
View QFR →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Tempus ECG-AF | QFR |
|---|---|---|
| Pricing | Contact vendor | Unknown |
| Deployment | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. | On-premise (integrates into cath lab environment) |
| BAA Available | Yes AI-estimated | Unknown |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Unknown |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Tempus ECG-AFTempus ECG-AF is designed without a dedicated user interface, integrating seamlessly into existing healthcare facility systems via standard communication protocols like APIs or file exchanges. This 'zero-click' approach minimizes changes to clinical workflows, enhancing usability.
Clinical Value
Tempus ECG-AFTempus ECG-AF is FDA-cleared and received Breakthrough Device Designation, indicating its significant advantage in identifying patients at risk of new-onset AF, with studies demonstrating its predictive capability for AF-related stroke. While QFR is also FDA-cleared, recent trials like FAVOR III Europe have shown it did not meet non-inferiority to FFR for clinical outcomes in routine practice.
Pricing & Value
Tempus ECG-AFTempus ECG-AF offers a clear value proposition with established CMS reimbursement available (CPT 0764T and CPT 0765T) and a specified Medicare rate of $128.90, effective January 1, 2025. QFR provides no public details regarding its pricing or reimbursement pathways.
Enterprise Readiness
Tempus ECG-AFTempus ECG-AF explicitly states HIPAA compliance and the availability of a Business Associate Agreement (BAA), which are crucial for enterprise adoption. It also integrates with major ECG systems and EHRs. QFR's HIPAA compliance is listed as 'unknown,' posing a potential barrier for enterprise deployment.
Innovation
Tempus ECG-AFTempus ECG-AF demonstrates significant innovation by leveraging AI to predict the risk of new-onset Atrial Fibrillation within 12 months from a standard, widely available 12-lead ECG. This predictive capability for proactive patient management, coupled with its FDA Breakthrough Device Designation, represents a unique advancement in early disease detection.
Support & Docs
Tempus ECG-AFTempus AI provides clear customer support channels, including a dedicated phone number and email address, with specified operating hours. In contrast, specific support or documentation information for QFR by QFR Solutions bv was not readily available through web searches.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Tempus ECG-AF | QFR |
|---|---|---|
| Tool Name | Tempus ECG-AF | QFR |
| Company | Tempus AI, Inc. | QFR Solutions bv |
| Description | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. | FDA-cleared AI-powered medical software for the visualization and quantitative flow ratio (QFR) analysis of X-ray angiographic images of coronary vessel segments, aiding cardiologists in lesion assessment. |
| Key Features | AI-based algorithm for 12-lead ECG analysis; Detects signs associated with new onset Atrial Fibrillation (AF) within 12 months; Intended for patients 65 years or older without pre-existing AF, pacemakers, ICDs, or recent cardiac surgery; Results interpreted in conjunction with other diagnostic information and clinical history; Compatible with FDA authorized resting 12-lead ECGs from GE Medical Systems and Philips Medical Systems; Trained on over 1.5 million ECGs from over 500,000 patients. | Visualization of X-ray angiographic images; Analysis and calculations in coronary vessel segments; Automatic detection and editing of vessel contours; 3D reconstruction of coronary vessel models; Accurate anatomical quantification of lesions; Quantitative Flow Ratio (QFR) assessment for functional significance; AI-enabled end-diastolic frame selection; Deep learning for precise alignment of angiographic projections. |
| Specialties | Cardiology, Geriatrics, Internal Medicine | Cardiology |
Videos
Demos, reviews, and walkthroughs featuring Tempus ECG-AF and QFR.